Zydus Lifesciences Limited vs Cipla Limited
An objective side-by-side of ZYDUSLIFE and CIPLA, both in Pharmaceuticals - Indian - Bulk Drugs & Formln: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: ZYDUSLIFE Mar 2026 · CIPLA Jun 2026
At a glance
- Zydus Lifesciences Limited is the larger company by market value, about 1.0 times the size of Cipla Limited.
- On trailing earnings, Zydus Lifesciences Limited trades at the lower P/E (27.2 against 33.4).
- Zydus Lifesciences Limited earns the higher return on equity (15.7% against 9.7%).
- Over three years Zydus Lifesciences Limited has grown profits faster (32% a year against 10%).
- Over the past year the share prices returned +12.0% (ZYDUSLIFE) and -10.5% (CIPLA).
| Metric | Zydus Lifesciences ZYDUSLIFE |
Cipla CIPLA |
|---|---|---|
| Size and price | ||
| Market cap | ₹115,810 Cr | ₹111,977 Cr |
| Share price | ₹1,161 | ₹1,386 |
| Valuation | ||
| P/E | 27.18 | 33.36 |
| P/B | 4.27 | 3.25 |
| EV/EBITDA | 18.71 | 21.26 |
| PEG | 0.85 | 3.34 |
| Dividend yield | 0.1% | 0.9% |
| Profitability | ||
| ROE | 15.7% | 9.7% |
| ROCE | 21.0% | 15.0% |
| Operating margin | 35.5% | 18.7% |
| Sales (TTM) | ₹19,316 Cr | ₹28,324 Cr |
| Net profit (TTM) | ₹4,261 Cr | ₹3,356 Cr |
| Growth | ||
| Latest quarter sales YoY | +16.2% | +2.3% |
| Latest quarter profit YoY | +14.5% | -39.2% |
| Sales CAGR 3Y | +16.0% | +7.0% |
| Profit CAGR 3Y | +32.0% | +10.0% |
| Sales CAGR 5Y | +12.0% | +8.0% |
| Profit CAGR 5Y | +19.0% | +10.0% |
| Financial strength | ||
| Debt/Equity | 0.46 | 0.02 |
| Interest cover | 13.34 | 86.10 |
| Ownership | ||
| Promoter holding | 75.0% | 29.2% |
| Promoter change (4 qtrs) | +0.00 pp | +0.02 pp |
| Price performance | ||
| Return 1M | +4.81% | -3.61% |
| Return 3M | +6.96% | -2.09% |
| Return 1Y | +11.97% | -10.48% |
| Return YTD | +26.98% | -8.28% |
| Technical condition | ||
| Technical score | 78 | 37 |
| RS rating (1-99) | 73.00 | 47.00 |
| % vs 200-DMA | +15.93% | -0.07% |
| RSI (14) | 55.92 | 45.81 |
| % from 52-week high | -3.65% | -17.15% |
